GSK's Jideytro Shows Competitive Profile for Lung Cancer Label Expansion

GSK's new lung-cancer drug Jideytro has shown a competitive profile for potential label expansion in 2027, according to analysts at J.P. Morgan. The drug helped delay disease progression for 90% of patients in a clinical trial, and efficacy looks competitive with Nuvation's Ibtrozi. Peak sales are estimated at 900 million pounds. Investors are now focused on the launch trajectory for Jideytro as a second-line treatment, with a potential expansion to first line in the second half of 2027. Shares rose 3.5%.